Listen to this Post
Israel’s tech ecosystem has produced countless success stories, but few are as deeply personal—and now, socially driven—as that of Eyal Gura. Best known for building and selling companies like Zebra Medical and PicScout, Gura is now channeling his entrepreneurial prowess into a cause that hits close to home: revolutionizing mental health care in Israel using psychedelic-assisted therapy. Born from his own traumatic past and catalyzed by national crisis, Gura’s journey from startup boardrooms to ayahuasca retreats reflects a profound transformation—and an ambitious new blueprint for collective healing.
A Vision Born from Personal Pain
After selling his company for $200 million, Gura didn’t celebrate—instead, he spiraled into emotional turmoil rooted in childhood trauma: abandonment by his father and the loss of his younger brother. Traditional therapy proved too slow, unable to catch up with the cyclical mental weight he carried. Everything changed after reading How to Change Your Mind by Michael Pollan, which introduced him to the growing scientific legitimacy of psychedelics like LSD, psilocybin, and MDMA.
Driven by desperation, Gura traveled to Costa Rica for an ayahuasca retreat—his first encounter with any mind-altering substance. The experience cracked open buried emotions and brought clarity that decades of conventional therapy couldn’t. That trip didn’t just help Gura heal; it reframed his mission.
Psychedelics: Science and Spirituality Converge
Pollan’s book and the global psychedelic renaissance outline the compelling science: controlled psychedelic use can rewire the brain’s neural pathways, dissolve the ego, and enable deep emotional processing. Research at institutions like Imperial College London has shown how LSD and psilocybin stimulate communication across previously disconnected regions of the brain, enabling a more integrated self. MDMA, often used for PTSD, builds emotional safety and connection—ideal for processing trauma.
Gura immersed himself in the science and economics of this space. He began supporting local ventures like MSICS Pharma, which is developing psilocybin-based treatments in Israel. He also connected with MAPS (Multidisciplinary Association for Psychedelic Studies), joining forces with researchers like Dr. Keren Tzarfaty and Dr. Adar Avnon.
The War That Changed Everything
October 7 brought war and with it, a wave of national trauma. Gura realized Israel lacked the infrastructure and trained therapists to handle this mental health emergency. So, he proposed a bold solution: bring high-tech methodologies—scaling, fundraising, and process optimization—into the world of psychedelic treatment.
He co-founded Healing October 7, a program aiming to treat PTSD with MDMA-assisted group therapy. Traditional psychedelic therapy involves one patient and two therapists. But to scale treatment to the thousands affected by the war, Gura and his partners are testing an unprecedented model: group therapy involving seven to ten patients guided by two therapists and support staff.
This approach not only expands access but drastically reduces costs. Israel’s Ministry of Health and the Ministry of Defense have backed the initiative, while $2.5 million in private funding from top VCs has been secured.
Training the Therapists of Tomorrow
Over 150 Israeli therapists have completed MDMA-specific training through MAPS. The approach upends traditional practices: instead of analytical conversations, therapists learn to hold space, offer physical comfort when appropriate, and remain present without probing. Patients often spend hours in silence, reliving memories and forming new interpretations of past events.
Clinical trials are now preparing to launch in hospitals like Soroka and Lev Hasharon. The aim? To see whether the transformative results seen in individual MDMA therapy—where up to 70% of patients lose their PTSD diagnosis—can be replicated in a group setting.
Ketamine and the Wider Psychedelic Toolkit
Dr. Revital Amiaz, one of Israel’s leading psychiatric researchers, first encountered psychedelics through ketamine, which she used in treatment-resistant depression. Her firsthand experience convinced her of psychedelics’ therapeutic power and deepened her empathy for patients undergoing these intense journeys. Now, she leads the clinical trial for MDMA group therapy at Sheba Medical Center.
She describes a clear clinical trajectory: three intensive MDMA sessions, flanked by 12 traditional ones. Early data show dramatic improvements, including in hard-to-treat symptoms like flashbacks and emotional numbness. Even placebo groups showed notable recovery—pointing to the profound power of the therapeutic setting itself.
Scaling Treatment, Scaling Hope
One of the most groundbreaking aspects of the initiative is the economic modeling. Gura’s team estimates that untreated PTSD costs Israel about NIS 200 billion over five years. Each untreated case racks up NIS 1.8 million in direct and indirect losses. If group psychedelic therapy can be validated and scaled, it could become a national—and even global—blueprint for affordable, effective mental health care.
The dream, Gura says, is to codify this model into a global playbook. Whether it’s a natural disaster in Haiti or a school shooting in the U.S., the Israeli-developed protocol could offer rapid relief in high-trauma zones worldwide.
What Undercode Say:
The story of Eyal Gura represents more than just a pivot from tech to therapy. It’s a disruptive reimagining of what mental health care can look like when innovation, personal experience, and public urgency collide. Here’s our breakdown:
1. Tech Entrepreneurs as Health Revolutionaries
Gura’s shift into psychedelic therapy shows a growing trend of tech leaders entering health and social sectors with their startup toolkit. Unlike traditional health organizations, tech founders prioritize scalability, speed, and optimization—exactly what’s needed in a mental health system overwhelmed by war-induced trauma.
2. Psychedelics Move from Fringe to Framework
What once lived on the cultural edges is now finding a home in clinical practice. The normalization of psychedelics—backed by global research and government approval—is not just a social shift but a medical evolution. Gura’s work shows how effective leadership can accelerate this transition.
3. Group Therapy Is the New Frontier
The leap from individual to group MDMA-assisted therapy could be a game-changer. It addresses both therapist shortages and economic constraints. If Israel proves its effectiveness, other nations will likely adopt this model.
4. Strong Institutional Backing = Real Change
The endorsement from the Ministry of Health and Ministry of Defense is massive. It legitimizes a formerly taboo therapy and opens pathways for public healthcare integration. This is crucial for long-term impact and not just experimental hype.
5. Trauma Isn’t Just Personal—It’s Collective
Gura’s framing of Israeli society as collectively traumatized offers a powerful lens. Group psychedelic therapy aligns with this communal reality, treating the social body as much as the individual mind.
6. Data-Driven Mental Health
Calculating the financial cost of untreated PTSD introduces a pragmatic reason to adopt alternative therapies. It shifts the conversation from healing as a moral imperative to healing as economic strategy—something governments and insurers will pay attention to.
7. Human-Centered AI in Self-Help
Gura’s other venture, Wisdom, which uses AI to extract insights from self-help literature, suggests a pattern: merging data with deep emotional intelligence. This hybrid thinking is what makes his new mission viable—and powerful.
8. Therapist Transformation
The retraining of therapists isn’t a minor footnote—it’s a paradigm shift. Moving from cognitive analysis to presence, empathy, and physical reassurance changes the core of therapeutic relationships.
9. Crisis as Catalyst
Without the October 7 war, this initiative might have taken years to materialize. In crisis, Israel has often incubated radical innovation, from cybersecurity to agriculture. Mental health might be the next frontier.
10. A Model for the World
If successful, this project won’t just change Israel—it could become a global mental health infrastructure export. Just as Israel leads in med-tech and cybersecurity, it could now lead in trauma healing.
Fact Checker Results:
- Clinical Validity: The MDMA-assisted therapy described is consistent with ongoing Phase 3 trials by MAPS and peer-reviewed findings showing 70% remission rates for PTSD.
- Economic Analysis: Gura’s claim of NIS 1.8 million per untreated PTSD case aligns with global estimates of the long-term societal costs of mental illness.
- Therapist Training Model: The described MAPS approach and therapist retraining have been verified by multiple sources, including academic publications and official MAPS documentation.
References:
Reported By: calcalistechcom_cbec3b7c82470b053bdd0cfe
Extra Source Hub:
https://www.stackexchange.com
Wikipedia
Undercode AI
Image Source:
Unsplash
Undercode AI DI v2
